(Bloomberg) -- The great tech selloff of 2022 is far from over as investors brace for earnings misses that may spur a more than 10% plunge in the Nasdaq 100.Most Read from BloombergJohn Paulson on Frothy US Housing Market: This Time Is DifferentBank of England Says Paper Banknotes Only Good for One More WeekThe Great Bond Bubble Is ‘Poof, Gone’ in Worst Year Since 1949‘Read Putin More Often and Carefully,’ Lavrov Tells the WorldUK Market Plunge Sparks Talk of Emergency BOE Rate HikeMore than two
There are certain products that will generally cost you more money at Costco, so you're better off buying them at the grocery store instead. Pasta is a staple item in many people's pantries -- certainly in mine. Pasta is one of those items that supermarkets tend to discount.
Three Motley Fool contributors have joined this roundtable to scour the market for some exciting initial public offerings (IPOs) in the healthcare field. Alex Carchidi (Amylyx Pharmaceuticals): Amylyx is worth owning because there's a solid chance it'll soon commercialize the first treatment for amyotrophic lateral sclerosis (ALS) that prolongs survival time while also slowing the disease's progression. Its medicine, AMX0035, has been approved for sale in Canada since late July, and regulators at the U.S. Food and Drug Administration will weigh in on the company's application for commercialization on Sept. 29.